PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs-Reference-Cited by-同舟云学术

PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs

Published:2022-05 Issue: Volume:345 Page:62-74
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Kim Eun Hye,Lee Jongwon,Kwak Gijung,Jang Hochung,Kim Hyosuk,Cho Haeun,Jang Yeongji,Choi Jiwoong,Chi Sung-Gil,Kim Kwangmeyung,Kwon Ick Chan,Yang Yoosoo,Kim Sun Hwa

Funder

National Research Foundation of Korea

Korea Institute of Science and Technology

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference42 articles.

1. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases;Rupaimoole;Nat. Rev. Drug Discov.,2017

2. Extracellular miRNAs: from biomarkers to mediators of physiology and disease;Mori;Cell Metab.,2019

3. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment;Kohlhapp;Oncogene,2015

4. Oncogenic MicroRNAs: key players in malignant transformation;Frixa;Cancers (Basel),2015

5. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis;Ma;Proc. Natl. Acad. Sci. U. S. A.,2011

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress;Molecular Therapy - Nucleic Acids;2024-09

2. Design of PD‐L1‐Targeted Lipid Nanoparticles to Turn on PTEN for Efficient Cancer Therapy;Advanced Science;2024-03-23

3. Targeted delivery of anti-miRNA21 sensitizes PD-L1^high tumor to immunotherapy by promoting immunogenic cell death;Theranostics;2024

4. RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges;Advanced Drug Delivery Reviews;2023-10

5. Design of siRNA Bioconjugates for Efficient Control of Cancer-Associated Membrane Receptors;ACS Omega;2023-09-22